Terms: = Ovarian cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
924 results:
1. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract] [Full Text] [Related]
2. A Survival Analysis of Patients with Recurrent Epithelial ovarian cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.
Harutyunyan L; Manvelyan E; Karapetyan N; Bardakhchyan S; Jilavyan A; Tamamyan G; Avagyan A; Safaryan L; Zohrabyan D; Movsisyan N; Avinyan A; Galoyan A; Sargsyan M; Harutyunyan M; Nersoyan H; Stepanyan A; Galstyan A; Danielyan S; Muradyan A; Jilavyan G
Curr Oncol; 2024 Mar; 31(3):1323-1334. PubMed ID: 38534933
[TBL] [Abstract] [Full Text] [Related]
3. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT; Cini JK; Dexter S; DaFonseca M; Bingham J; Kuan I; Chawla SP; Polasek TM; Lickliter J; Ryan PJ
Front Immunol; 2024; 15():1362775. PubMed ID: 38487528
[TBL] [Abstract] [Full Text] [Related]
4. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N; Ciliberto D; Luciano F; Napoli C; Costa M; Rossini G; Arbitrio M; Labanca C; Riillo C; Del Giudice T; Crispino A; Salvino A; Galvano A; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2024 Jan; 193():104229. PubMed ID: 38065404
[TBL] [Abstract] [Full Text] [Related]
5. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab treatment in Patients with Advanced ovarian cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract] [Full Text] [Related]
6. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
7. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM; O'Malley DM; Monk BJ; Coleman RL; Gaillard S; Adams S; Duska LR; Dalton H; Holloway RW; Huang M; Chon HS; Cloven NG; ElNaggar AC; O'Cearbhaill RE; Waggoner S; Tarkar A; Striha A; Nelsen LM; Baines A; Samnotra V; Konstantinopoulos PA
Gynecol Oncol; 2023 Nov; 178():161-169. PubMed ID: 37890345
[TBL] [Abstract] [Full Text] [Related]
8. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
9. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
10. Assisted reproductive technology use and outcomes in childhood cancer survivors.
Keefe KW; Lanes A; Stratton K; Green DM; Chow EJ; Oeffinger KC; Barton S; Diller L; Yasui Y; Leisenring WM; Armstrong GT; Ginsburg ES
Cancer; 2024 Jan; 130(1):128-139. PubMed ID: 37732943
[TBL] [Abstract] [Full Text] [Related]
11. Cellular and extracellular vaginal changes following murine ovarian removal.
McCracken JM; Calderon GA; Le QN; Faruqui NM; Balaji S; Hakim JCE
Physiol Rep; 2023 Aug; 11(15):e15762. PubMed ID: 37549960
[TBL] [Abstract] [Full Text] [Related]
12. Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for ovarian cancer: A Secondary Analysis of a Randomized Clinical Trial.
Cao A; Cartmel B; Li FY; Gottlieb LT; Harrigan M; Ligibel JA; Gogoi R; Schwartz PE; Esserman DA; Irwin ML; Ferrucci LM
JAMA Netw Open; 2023 Aug; 6(8):e2326463. PubMed ID: 37526937
[TBL] [Abstract] [Full Text] [Related]
13. The Evolving Spectrum of Endometrial Glandular Proliferations With Corded and Hyalinized Features.
Pors J; Weiel JJ; Ryan E; Longacre TA
Am J Surg Pathol; 2023 Sep; 47(9):1067-1076. PubMed ID: 37493099
[TBL] [Abstract] [Full Text] [Related]
14. A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Horvat N; Causa Andrieu P; Meier A; Ji X; Lakhman Y; Soslow R; Allison D; Gangai N; Rodriguez L; Kattan MW; Chi DS; Hricak H
Gynecol Oncol; 2023 Sep; 176():90-97. PubMed ID: 37478617
[TBL] [Abstract] [Full Text] [Related]
15. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
Porter RL; Matulonis UA
Expert Rev Anticancer Ther; 2023; 23(8):783-796. PubMed ID: 37458180
[TBL] [Abstract] [Full Text] [Related]
16. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering cancer Center Team Ovary study.
Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
[TBL] [Abstract] [Full Text] [Related]
17. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
18. Potentiation of Cisplatin Cytotoxicity in Resistant ovarian cancer SKOV3/Cisplatin Cells by Quercetin Pre-treatment.
Hasan AA; Kalinina E; Nuzhina J; Volodina Y; Shtil A; Tatarskiy V
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446140
[TBL] [Abstract] [Full Text] [Related]
19. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
[TBL] [Abstract] [Full Text] [Related]
20. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; deFazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Høgdall CK; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjańczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; van Altena AM; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A;
Can J Surg; 2023; 66(3):E310-E320. PubMed ID: 37369443
[TBL] [Abstract] [Full Text] [Related]
[Next]
